Two survey exercises are distributed each financial year. Each survey includes a minimum of one sample for ADAMTS13 assay - participants are invited to perform antigen, activity and inhibitor/antibody assays, to reflect their clinical practice.
All samples are of lyophilised plasma, from donors screened for hepatitis B surface antigen (HBsAg) and for antibodies to hepatitis C virus and human immunodeficiency virus types 1 and 2 (anti HIV-1+2).
Individual survey reports for each survey are made available within two weeks of the closing date for the respective survey. Reports are made available as paper copies, and email alerts are sent out about availability.
*Closing date provisionally set at 6 weeks post distribution, and reporting 3 weeks after this. The schedule may be amended depending on laboratories' ability to meet these timescales.